TNFRSF10B and glioblastoma: Second, several agents that upmodulate TRAIL-R2 expression in glioblastoma cells, such as cisplatin [30], lanatoside C [31], nelfinavir [32], the protesome inhibitor SC68896 [33] restore TRAIL sensitivity of glioblastoma cells.